About Remus Pharmaceuticals Limited
Data last updated:
Remus Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 21 September 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24232GJ2015PLC084536. Its GSTIN is 24AAHCR4771P2ZQ (Gujarat). The company holds 2 GST registrations, of which 1 is active. It is a listed company.
The company has an authorised share capital of ₹12.5 Cr and a paid-up capital of ₹11.78 Cr. It is led by directors including Arpit Deepakkumar Shah (Managing Director) and Roma Vinodbhai Shah (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Jayantilal Park, Ahmedabad, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹625.34 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net profit of ₹38.42 Cr (net margin 6.1%) and EBITDA of ₹50.67 Cr (EBITDA margin 8.1%). Revenue has grown at a compounded annual rate (CAGR) of 191% over three years and 118% over five years.
The company has about 34 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Remus Pharma. As per MCA filings, the company has open charges of ₹15.66 Cr and satisfied charges of ₹2 Cr on record. The company has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023. Its 10 peer companies in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Skites Pharma Private Limited. The company has 12 MSME Form 1 returns on record between 2018 and 2023, listing 325 overdue payments to 25 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website remuspharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address1101 To 1103 South Tower One 42 B/H Ashok Vatika Nr.Jayantilal Park Brts Ambli Bopal Roa, D, Ahmedabad, Gujarat, India – 380054
- IndustryTrading, Wholesale, Other Wholesale
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Remus Pharmaceuticals Limited
The main business activity of Remus Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Remus Pharmaceuticals Limited FY 2025 filings available
Remus Pharmaceuticals Limited reported revenue of ₹625.34 Cr (up 190% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Remus Pharmaceuticals Limited
Revenue has grown at a compounded annual rate (CAGR) of 118% over five years, including 190% growth in the latest year. EBITDA rose 59% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Remus Pharmaceuticals Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹50.67 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹38.42 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Remus Pharmaceuticals Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 8.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 6.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Remus Pharmaceuticals are in the company report.
Financial statements from FY 2016
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals). Revenue, net profit, margin and growth of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Skites Pharma Private Limited | •••• | •••• | •••• | •••• | 365 | Mumbai, Maharashtra, India |
| Lincoln Pharmaceuticals Ltd | •••• | •••• | •••• | •••• | - | Ahmedabad, Gujarat, India |
| Dhruvi Healthcare Private Limited | •••• | •••• | •••• | •••• | - | Ahemdabad, Gujarat, India |
| Theon Pharmaceuticals Limited | •••• | •••• | •••• | •••• | 978 | Chandigarh, India |
| Malladi Drugs and Pharmaceuticals Limited | •••• | •••• | •••• | •••• | 755 | Chennai, Tamil Nadu, India |
| Remus Pharmaceuticals Limited this company | •••• | •••• | •••• | •••• | - | Ahmedabad, Gujarat, India |
| Vardhman Health Specialities Private Limited | •••• | •••• | •••• | •••• | 233 | Bangalore South, Karnataka, India |
| Bayer Zydus Pharma Private Limited | •••• | •••• | •••• | •••• | 688 | Thane, Maharashtra, India |
| Auro Enterprises(India)Private Limited | •••• | •••• | •••• | •••• | - | Hyderabad, Telangana, India |
| Sri Krishna Pharmaceuticals Limited | •••• | •••• | •••• | •••• | 1,543 | Telangana, India |
| Sanyog Healthcare Limited | •••• | •••• | •••• | •••• | - | Delhi, India |
Peers are the five companies nearest above and the five nearest below Remus Pharmaceuticals by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), from the latest filed financials of each company. Revenue, net profit, margin and growth of each peer are in the company report.
Auditor Details of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited is audited by Parikh & Majmudar for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Parikh & Majmudar | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Remus Pharmaceuticals Limited
Remus Pharmaceuticals has 7 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Swapnil Jatinbhai Shah Also directs: Espee Therapeutics LLP, Aelius Projects LLP, Senores Pharmaceuticals Limited and 4 more | Director | 21 Sep 2015 | 11 Years 0 Months | Current |
| Anar Swapnil Shah Also directs: Espee Global Clinical Trial Services Private Limited, Espee Therapeutics LLP, Aelius Projects LLP and 5 more | Director | 30 Dec 2020 | 5 Years 9 Months | Current |
| Roma Vinodbhai Shah Also directs: Relius Lifesciences Private Limited | Whole-Time Director | 21 Sep 2015 | 11 Years 0 Months | Current |
| Vishrut Chandramauli Pathak Also directs: Indus Valley Research LLP, Pi Square Bridge Way Advisors LLP, Pi Square Bridge Way Long Short Fund (Ifsc) LLP and 4 more | Director | 06 Jan 2023 | 3 Years 9 Months | Current |
| Arpit Deepakkumar Shah | Managing Director | 21 Sep 2015 | 11 Years 0 Months | Current |
| Balwant Purohit | Director | 06 Jan 2023 | 3 Years 9 Months | Current |
Ownership and Shareholding of Remus Pharmaceuticals Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Remus Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Oct 2025 | Others | ₹49.9 Lakh | Open |
| 26 Sep 2025 | Hdfc Bank Limited | ₹10.48 Cr | Open |
| 26 Jun 2025 | Hdfc Bank Limited | ₹2.19 Cr | Open |
| 02 Sep 2024 | Hdfc Bank Limited | ₹1 Cr | Open |
| 26 Feb 2024 | Hdfc Bank Limited | ₹1.5 Cr | Open |
Total charge records: 6 View all charges
Deals & Funding of Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023.
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2023 | IPO | ₹47.69 Cr | Investors: Chhatisgarh Investments Limited , NAV Capital VCC |
| Dec 2022 | Funding round | ₹4.25 Cr | Investors: 4 individuals |
| Mar 2020 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Espee Lifescience Private Limited, an individual |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Espee Lifescience Private Limited |
Full deal history
All 4 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited has 12 MSME Form 1 returns on record between 2018 and 2023, listing 325 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Chase Logistics Private Limited | •••• | •••• | •••• |
| Suraj Print Pack Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Aelius Projects LLP | •••• | •••• | •••• |
| Auracare Pharma Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 12 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Remus Pharmaceuticals Limited
Remus Pharmaceuticals operates one associated brand: Remus Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Remus Pharma is engaged in providing healthcare solutions globally. | remuspharma.com |
Employees and EPFO Compliance at Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited has a workforce of 34 employees as of Apr 07, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Remus Pharmaceuticals Limited
Remus Pharmaceuticals has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24232GJ2015PLC084536, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232GJ2015PLC084536 | Current |
| U24232GJ2015PLC084536 | Previous |
| U24232GJ2015PTC084536 | Previous |
Recent Activity on Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited has 14 board changes on record since 2015: 7 appointments and 7 cessations. The latest: Balwant Purohit ceased to be Additional Director on 28 Feb 2023.
12 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Remus Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Remus Pharmaceuticals Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Remus Pharmaceuticals Limited
Remus Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAHCR4771P2ZQ | Gujarat | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Remus Pharmaceuticals Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Remus Pharmaceuticals Limited
Remus Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in wholesale, within the trading industry. It was incorporated on 21 September 2015 (11+ years old) and is registered under CIN L24232GJ2015PLC084536.
Remus Pharmaceuticals reported revenue of ₹625.34 Cr for FY 2025 (up 190% YoY).
Remus Pharmaceuticals has 7 current directors:
- Arpit Deepakkumar Shah - Managing Director
- Roma Vinodbhai Shah - Whole-Time Director
- Swapnil Jatinbhai Shah - Director
- Anar Swapnil Shah - Director
- Vishrut Chandramauli Pathak - Director
- Balwant Purohit - Director
- Sanjana Sanjeev Shah - Director
Remus Pharmaceuticals reported a net profit of ₹38.42 Cr (net margin 6.1%) and EBITDA of ₹50.67 Cr (EBITDA margin 8.1%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Remus Pharmaceuticals is 191% over three years and 118% over five years. In the latest year (FY 2025) revenue rose 190%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Remus Pharmaceuticals is 24AAHCR4771P2ZQ, registered in Gujarat. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Remus Pharmaceuticals is L24232GJ2015PLC084536. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes, Remus Pharmaceuticals is a listed company.
Remus Pharmaceuticals was incorporated on 21 September 2015, making it 11+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Remus Pharmaceuticals has 4 deals on record (2 secondary share transfers, 1 ipo, 1 funding round), with disclosed funding of ₹4.25 Cr; the latest was in May 2023.
The peers of Remus Pharmaceuticals by revenue are Skites Pharma Private Limited, Lincoln Pharmaceuticals Ltd, Dhruvi Healthcare Private Limited, Theon Pharmaceuticals Limited, Malladi Drugs and Pharmaceuticals Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals).
Balwant Purohit ceased to be Additional Director on 28 Feb 2023. Sanjana Sanjeev Shah ceased to be Additional Director on 28 Feb 2023. Vishrut Chandramauli Pathak ceased to be Additional Director on 28 Feb 2023. Remus Pharmaceuticals has 14 board changes on record in total.